RxDoctor Payments Data

Gary Chan, DO

Cardiovascular Disease · Canton, GANPI 1548649254

Payments from drug & device makers

$742in general payments, 2019–2025

Across 37 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$262
  • Merck$80
  • Amgen$74
  • E.r. Squibb & Sons, L.L.C.$69
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$60
  • AstraZeneca$52
  • plus $145 from 6 others

What the payments were for

  • Food & beverage$72898%
  • Education$142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$742 in reported general payments places this provider in the 25th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$68,466
Medicare patients
618
Services billed
1,297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban393$335,241
EntrestoSacubitril/Valsartan117$139,453
XareltoRivaroxaban89$73,213
FarxigaDapagliflozin Propanediol55$46,032
Repatha SureclickEvolocumab60$41,155
BrilintaTicagrelor33$26,637
CorlanorIvabradine Hcl20$25,344
VascepaIcosapent Ethyl36$14,385
Ezetimibe339$7,479
Metoprolol Succinate654$6,631
Atorvastatin Calcium778$4,747
Isosorbide Dinitrate57$3,864
Rosuvastatin Calcium336$3,110
Potassium Chloride155$2,827
Flecainide Acetate91$2,748

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$262$139,453117 claims
Johnson & JohnsonXarelto$18$73,21389 claims
AstraZenecaFarxiga, Brilinta$52$72,67088 claims
AmgenCorlanor$74$25,34420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Canton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →